Drug Information

Drug (ID: DG01744) and It's Reported Resistant Information

Name	Encorafenib/Trametinib
Synonyms	Encorafenib/Trametinib Click to Show/Hide

Type(s) of Resistant Mechanism of This Drug

UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Lung cancer [ICD-11: 2C25]

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Unusual Activation of Pro-survival Pathway (UAPP)		Click to Show/Hide
Key Molecule: Serine/threonine-protein kinase B-raf (BRAF)			[1]
Sensitive Disease	Lung adenocarcinoma [ICD-11: 2C25.0]		Disease Info
Molecule Alteration	Missense mutation	p.G469A (c.1406G>C)	Molecule Info
Experimental Note	Identified from the Human Clinical Data
Cell Pathway Regulation	MAPK signaling pathway	Inhibition	hsa04010
In Vitro Model	Skin sample		N.A.
In Vivo Model	Mouse PDX model		Mus musculus
Experiment for Drug Resistance	Crystal violet staining assay

References

Ref 1	Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant MelanomasClin Cancer Res. 2018 Dec 15;24(24):6483-6494. doi: 10.1158/1078-0432.CCR-17-3384. Epub 2018 Jun 14.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Yu.